Terms: = Kidney tumors AND HEY1, CHF-2, 23462, ENSG00000164683, HESR1, CHF2, HESR-1, MGC1274, HRT-1, OAF1, HERP2 AND Treatment
3 results:
1. LncRNA MAGI2-AS3 inhibits tumor progression and angiogenesis by regulating ACY1 via interacting with transcription factor hey1 in clear cell renal cell carcinoma.
Wang G; Li H; Hou Y
Cancer Gene Ther; 2022 May; 29(5):585-596. PubMed ID: 34002044
[TBL] [Abstract] [Full Text] [Related]
2. Cyclin D1 as a therapeutic target of renal cell carcinoma- a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia.
Karim S; Al-Maghrabi JA; Farsi HM; Al-Sayyad AJ; Schulten HJ; Buhmeida A; Mirza Z; Al-Boogmi AA; Ashgan FT; Shabaad MM; NourEldin HF; Al-Ghamdi KB; Abuzenadah A; Chaudhary AG; Al-Qahtani MH
BMC Cancer; 2016 Sep; 16(Suppl 2):741. PubMed ID: 27766950
[TBL] [Abstract] [Full Text] [Related]
3. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.
Thounaojam MC; Dudimah DF; Pellom ST; Uzhachenko RV; Carbone DP; Dikov MM; Shanker A
Oncotarget; 2015 Oct; 6(32):32439-55. PubMed ID: 26431276
[TBL] [Abstract] [Full Text] [Related]
